Third Harmonic Bio, Inc. (THRD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

The MAD cohort also saw adverse events such as hair loss and reductions in hemoglobin and neutrophil counts. These side ...

What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Friday showed that BenNatan purchased 7,780 shares of Harmonic. The total transaction amounted to $75,060. Harmonic ...

Third Harmonic Bio, Inc. (NASDAQ:THRD) revealed results from its Phase 1 single and multiple ascending dose (SAD/MAD) trial ...

Harmonic Inc. (NASDAQ:HLIT – Get Free Report) reached a new 52-week low during trading on Tuesday after Rosenblatt Securities ...

Harmonic (NASDAQ:HLIT – Get Free Report) declared that its board has initiated a stock repurchase plan on Monday, February ...

Walter Jankovic, Chief Financial Officer at Harmonic HLIT executed a significant insider buy, as disclosed in the latest SEC filing. What Happened: Jankovic made a significant move by purchasing ...

Harmonic expects full-year earnings in the range of 43 cents to 68 cents per share, with revenue ranging from $585 million to $645 million. This story was generated by Automated Insights ( ...

Harmonic's shares fell after the company's earnings forecast for the current quarter and the year fell short of analysts' expectations. The stock slid 31%, to $7.69, in post-market trading Monday.

Collaboration Qualifies Two Harmonic Video Streaming Solutions, VOS360 Media and VOS360 Ad SaaS, on Akamai Cloud ...

THB335 Phase 1 data support advancement into Phase 2 clinical trial in chronic spontaneous urticaria (CSU)Company initiating process to leverage ...